HK1036937A1 - Matrix tablet enabling the prolonged release of trimetazidine after administration by the oral route. - Google Patents

Matrix tablet enabling the prolonged release of trimetazidine after administration by the oral route.

Info

Publication number
HK1036937A1
HK1036937A1 HK01107928A HK01107928A HK1036937A1 HK 1036937 A1 HK1036937 A1 HK 1036937A1 HK 01107928 A HK01107928 A HK 01107928A HK 01107928 A HK01107928 A HK 01107928A HK 1036937 A1 HK1036937 A1 HK 1036937A1
Authority
HK
Hong Kong
Prior art keywords
trimetazidine
administration
oral route
prolonged release
matrix tablet
Prior art date
Application number
HK01107928A
Other languages
English (en)
Inventor
De Barochez Bruno Huet
Claude Dauphant
Patrick Wuthrich
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9553398&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1036937(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of HK1036937A1 publication Critical patent/HK1036937A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK01107928A 1999-12-17 2001-11-12 Matrix tablet enabling the prolonged release of trimetazidine after administration by the oral route. HK1036937A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9915960A FR2802424B1 (fr) 1999-12-17 1999-12-17 Comprime matriciel permettant la liberation prolongee de trimetazidine apres administration par voie orale

Publications (1)

Publication Number Publication Date
HK1036937A1 true HK1036937A1 (en) 2002-01-25

Family

ID=9553398

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01107928A HK1036937A1 (en) 1999-12-17 2001-11-12 Matrix tablet enabling the prolonged release of trimetazidine after administration by the oral route.

Country Status (33)

Country Link
EP (1) EP1108424B2 (sk)
JP (2) JP2001172181A (sk)
KR (1) KR100456933B1 (sk)
CN (1) CN1166408C (sk)
AR (1) AR026968A1 (sk)
AT (1) ATE296622T1 (sk)
AU (1) AU780011B2 (sk)
BG (1) BG65773B1 (sk)
BR (1) BR0005915A (sk)
CY (1) CY2347B1 (sk)
CZ (1) CZ299461B6 (sk)
DE (1) DE60020501T3 (sk)
DK (1) DK1108424T4 (sk)
EA (2) EA200501901A1 (sk)
ES (2) ES2240033T5 (sk)
FR (1) FR2802424B1 (sk)
GE (1) GEP20053540B (sk)
GR (1) GR1003658B (sk)
HK (1) HK1036937A1 (sk)
HU (1) HU226956B1 (sk)
IE (1) IE20001017A1 (sk)
IT (1) IT1317075B1 (sk)
LU (1) LU90700B1 (sk)
MX (1) MXPA00012462A (sk)
NZ (1) NZ508912A (sk)
OA (1) OA12121A (sk)
PL (1) PL206994B1 (sk)
PT (2) PT102542A (sk)
SI (1) SI1108424T2 (sk)
SK (1) SK286752B6 (sk)
UA (1) UA80087C2 (sk)
WO (1) WO2001043747A1 (sk)
ZA (1) ZA200007548B (sk)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1195160B1 (en) * 2000-10-05 2009-09-16 USV Ltd. Sustained release trimetazidine pharmaceutical compositions and a method of their preparation
WO2005011682A1 (ja) * 2003-08-04 2005-02-10 Kyorin Pharmaceutical Co., Ltd. 経口徐放性錠剤
SG126792A1 (en) * 2005-04-27 2006-11-29 Servier Lab Matrix tablet enabling the prolonged release of trimetazidine after administration by the oral route
FR2885807B1 (fr) * 2005-05-18 2008-05-16 Mg Pharma Composition pharmaceutique solide a liberation prolongee de 1-(2,3,4-trimethoxybenzyl) piperazine, et procede de preparation
CZ300307B6 (cs) * 2006-01-04 2009-04-15 Zentiva, A. S. Tableta s obsahem trimetazidinu nebo jeho farmakologicky akceptovatelné soli s modifikovaným uvolnováním
EA009776B1 (ru) * 2006-07-18 2008-04-28 Мераб Ревазович Кокеладзе Способ изготовления таблетированной лекарственной формы триметазидина дигидрохлорида и ее состав
EA009810B1 (ru) * 2006-12-26 2008-04-28 Закрытое Акционерное Общество "Канонфарма Продакшн" Матрица для изготовления таблетированной лекарственной формы и способ лечения
EP2200591A2 (en) * 2007-09-11 2010-06-30 Ranbaxy Laboratories Limited Controlled release pharmaceutical dosage forms of trimetazidine
US20110300209A1 (en) 2009-01-20 2011-12-08 Micro Labs Limited Modified release solid pharmaceutical compositions of trimetazidine and process thereof
WO2010086868A1 (en) * 2009-01-30 2010-08-05 Lupin Limited Pharmaceutical compositions of trimetazidine
TR201001902A2 (tr) 2010-03-12 2011-04-21 Ali̇ Rai̇f İlaç Sanayi̇ Ve Ti̇caret A.Ş. Uzatılmış salınımlı trimetazidin tablet
RU2445958C2 (ru) * 2010-04-20 2012-03-27 Общество с ограниченной ответственностью "Озон" (ООО "Озон") Матричная таблетка с основой для пролонгированного высвобождения триметазидина и способ ее изготовления
EP2394644B1 (en) 2010-05-04 2014-07-09 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Trimetazidine Formulation With Different Release Profiles
EP2386302A1 (en) 2010-05-11 2011-11-16 Ranbaxy Laboratories Limited A controlled release pharmaceutical dosage form of trimetazidine and processes for the preparation thereof
EP2491930A1 (en) 2011-02-25 2012-08-29 Deva Holding Anonim Sirketi Pharmaceutical combination of betahistine and trimetazidine
FR2978916B1 (fr) * 2011-08-10 2013-07-26 Servier Lab Composition pharmaceutique solide pour administration buccale d'agomelatine
FR2986431B1 (fr) * 2012-02-03 2017-03-17 Servier Lab Composition pharmaceutique a liberation prolongee de trimetazidine, son procede de fabrication et son utilisation dans des traitements therapeutiques
CN102824644B (zh) * 2012-09-13 2013-12-25 浙江诚意药业有限公司 使用羟丙基纤维素制备的高稳定性的缓释片
KR20160118733A (ko) 2015-04-03 2016-10-12 이인현 호스 권취용 호스 안내장치 및 이를 구비한 호스 권취기
CN109316455B (zh) * 2017-07-31 2021-05-25 北京福元医药股份有限公司 一种盐酸曲美他嗪缓释片
CN109908096A (zh) * 2017-12-12 2019-06-21 武汉武药科技有限公司 一种盐酸曲美他嗪缓释片及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4226849A (en) * 1979-06-14 1980-10-07 Forest Laboratories Inc. Sustained release therapeutic compositions
FR2490963B1 (fr) * 1980-09-30 1986-04-18 Science Union & Cie Nouvelle composition therapeutique a action anti-ischemique contenant de la trimethoxy 2, 3, 4-benzyl 1-piperazine
KR850006132A (ko) * 1984-02-29 1985-10-02 진 크라메르, 한스 루돌프 하우스 브로모크립틴 조성물
JPS61293931A (ja) * 1985-06-24 1986-12-24 Teijin Ltd 徐放性医薬品組成物
JPH0625055B2 (ja) * 1985-03-18 1994-04-06 日本ケミフア株式会社 持続性錠剤
EP0207638B1 (en) † 1985-06-04 1990-12-19 Teijin Limited Sustained-release pharmaceutical preparation
SE455836B (sv) * 1985-10-11 1988-08-15 Haessle Ab Beredning med kontrollerad frisettning innehallande ett salt av metoprolol samt metod for framstellning av denna beredning
SE8601624D0 (sv) * 1986-04-11 1986-04-11 Haessle Ab New pharmaceutical preparations
FR2677886B1 (fr) * 1991-06-18 1995-03-31 Adir Comprime matriciel permettant la liberation prolongee d'indapamide apres administration par voie orale.
FR2681324B1 (fr) * 1991-09-18 1993-10-29 Adir Cie Nouveaux derives de la trimetazidine, leur procede de preparation et les compositions pharmaceutiques les contenant.
KR940021051A (ko) * 1993-03-03 1994-10-17 손정삼 3단계 약물방출형 지속성 정제
RU2082400C1 (ru) * 1993-12-16 1997-06-27 Акционерное общество - Фармацевтическая фирма "Ник-Фарм" Способ получения нитроглицерина пролонгированного действия
FR2717687B1 (fr) * 1994-03-24 1996-06-14 Adir Compositions pharmaceutiques permettant la libération prolongée de trimétazidine après administration par voie orale.

Also Published As

Publication number Publication date
DE60020501T3 (de) 2014-03-20
KR20010062478A (ko) 2001-07-07
EP1108424A1 (fr) 2001-06-20
OA12121A (en) 2003-10-20
SI1108424T2 (sl) 2014-02-28
GR1003658B (el) 2001-09-05
FR2802424A1 (fr) 2001-06-22
ES2176106A1 (es) 2002-11-16
AR026968A1 (es) 2003-03-05
JP2001172181A (ja) 2001-06-26
DK1108424T3 (da) 2005-10-03
CN1302663A (zh) 2001-07-11
ES2240033T3 (es) 2005-10-16
HUP0004966A2 (en) 2002-06-29
BG106927A (en) 2003-05-30
UA80087C2 (en) 2007-08-27
GEP20053540B (en) 2005-06-10
EA200001201A2 (ru) 2001-08-27
SK8632002A3 (en) 2002-10-08
IE20001017A1 (en) 2002-04-03
EA200001201A3 (ru) 2001-10-22
WO2001043747A1 (fr) 2001-06-21
EA200501901A1 (ru) 2006-06-30
HU226956B1 (en) 2010-03-29
EA008223B1 (ru) 2007-04-27
ES2240033T5 (es) 2014-01-16
FR2802424B1 (fr) 2002-02-15
SK286752B6 (sk) 2009-04-06
AU780011B2 (en) 2005-02-24
LU90700B1 (fr) 2007-12-03
DE60020501D1 (de) 2005-07-07
BG65773B1 (bg) 2009-11-30
CZ20022082A3 (cs) 2002-09-11
DK1108424T4 (da) 2013-12-16
HU0004966D0 (sk) 2001-02-28
NZ508912A (en) 2002-04-26
ITRM20000667A0 (it) 2000-12-14
SI1108424T1 (en) 2005-10-31
ITRM20000667A1 (it) 2002-06-14
IT1317075B1 (it) 2003-05-26
ES2176106B1 (es) 2004-01-16
PT102542A (pt) 2001-06-29
ATE296622T1 (de) 2005-06-15
DE60020501T2 (de) 2006-04-27
EP1108424B2 (fr) 2013-09-04
JP2007314578A (ja) 2007-12-06
PL206994B1 (pl) 2010-10-29
CY2347B1 (en) 2004-06-04
EP1108424B1 (fr) 2005-06-01
PL344564A1 (en) 2001-06-18
PT1108424E (pt) 2005-08-31
CN1166408C (zh) 2004-09-15
MXPA00012462A (es) 2002-06-04
WO2001043747A8 (fr) 2001-09-07
KR100456933B1 (ko) 2004-11-10
BR0005915A (pt) 2001-10-02
HUP0004966A3 (en) 2008-04-28
ZA200007548B (en) 2001-06-19
AU7228500A (en) 2001-06-21
CZ299461B6 (cs) 2008-08-06

Similar Documents

Publication Publication Date Title
CY2347B1 (en) Matrix tablet enabling the prolonged release of trimetazidine after administration by the oral route.
HRP20010632A2 (en) Matrix tablet enabling prolonged release of gliclazide after administration by the oral route
HK1034455A1 (en) Oral pharmaceutical extended release dosage form.
ZA200007714B (en) Extended release oral dosage composition.
ZA200007715B (en) Stable extended release oral dosage composition.
ZA200202480B (en) Oral dosage forms.
MXPA03003235A (es) Formulaciones farmaceuticas de liberacion retrasada.
AU3574500A (en) Rapidly disintegrable tablet for oral administration
HK1045650A1 (en) Pharmaceutical composition.
ZA995445B (en) Extended release buccal tablet.
HUP0301242A3 (en) Controlled release drug dosage form
AU6089200A (en) Rapid immediate release oral dosage form
ZA993338B (en) Pharmaceutical formulations.
ZA200107123B (en) Oral drug delivery system.
MXPA01012478A (es) Formulaciones farmaceuticas mejoradas.
ZA200203486B (en) Novel pharmaceutical compositions.
MXPA03002569A (es) Formulaciones de liberacion controlada para administracion oral.
IL146632A0 (en) Pharmaceutical tablets
HRPK20010706B1 (en) Tolperison-containing, pharmaceutical preparation for oral administration
ZA200000857B (en) Pharmaceutical composition.
EP1207852A4 (en) ORAL PHARMACEUTICALS WITH TAXED RELEASE FOR ORAL ADMINISTRATION
HK1040488A1 (en) Pharmaceutical formulations.
EP1173216A4 (en) PHARMACEUTICAL FORMULATIONS
ZA200110401B (en) Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
HK1046133A1 (en) Pharmaceutical compounds.

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20201214